Introduction: Addressing Livestock Reproductive Efficiency, Estrus Synchronization, and Veterinary API Supply
For livestock producers, veterinarians, and animal health product manufacturers, reproductive efficiency directly impacts productivity in swine, cattle, sheep, and horse operations. PMSG (pregnant mare serum gonadotropin) is a glycoprotein hormone extracted from the serum of pregnant mares (days 40–120 of gestation), exhibiting both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) biological activities. PMSG stimulates ovarian follicle development (FSH activity), induces ovulation (LH activity), and enhances fertility (litter size, conception rate, pregnancy rate). As global demand for animal protein increases (pork, beef, lamb, dairy), livestock producers adopt assisted reproductive technologies (estrus synchronization, fixed-time artificial insemination, embryo transfer, superovulation), and veterinary API supply chains focus on purity, potency, and batch-to-batch consistency, demand for PMSG API is growing. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pregnant Mare Serum Gonadotropin (PMSG) API – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pregnant Mare Serum Gonadotropin (PMSG) API market, including market size, share, demand, industry development status, and forecasts for the next few years.
For veterinary pharmaceutical procurement managers, livestock production directors, and animal health investors, the core pain points include achieving high biological potency (FSH/LH activity), batch-to-batch consistency (purity, sterility, stability), and compliance with regulatory standards (EMA, FDA-CVM, CFIA). According to QYResearch, the global PMSG API market was valued at US$ 134 million in 2025 and is projected to reach US$ 183 million by 2032, growing at a CAGR of 4.6% . In 2024, global production reached approximately 45.25 billion IU, with an average price of US$ 2.80 per 1,000 IU.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/6096843/pregnant-mare-serum-gonadotropin–pmsg–api
Market Definition and Core Capabilities
Pregnant Mare Serum Gonadotropin (PMSG) API is a glycoprotein hormone extracted from pregnant mare serum, exhibiting both FSH and LH activities, used in veterinary medicine to induce estrus, stimulate ovulation, and enhance fertility in livestock species. Core capabilities:
- Extraction & Purification: Serum collected from pregnant mares (days 40–120 gestation). Purification (precipitation, chromatography, ultrafiltration) removes impurities (proteins, endotoxins, viruses). Lyophilization (freeze-drying) for stability (long-term storage). Stabilizers (sugars, amino acids) preserve biological activity.
- Biological Activity: FSH (follicle-stimulating hormone) activity – stimulates ovarian follicle development (growth, maturation). LH (luteinizing hormone) activity – induces ovulation (follicle rupture, corpus luteum formation). Ratio FSH:LH (1:1 to 1:2) varies by extraction batch.
- Potency: 1000 IU/mg – lower potency, lower cost, bulk API for general livestock. 5000 IU/mg – higher potency, higher cost, for high-value livestock (embryo transfer, superovulation). Potency determined by bioassay (rat ovarian weight gain, mouse uterine weight gain).
- Applications: Estrus synchronization (fixed-time artificial insemination, FTAI). Ovulation induction (timed breeding). Superovulation (embryo transfer, multiple ovulation, genetic improvement). Treatment of ovarian dysfunction (cystic ovaries, anestrus, silent heat).
Market Segmentation by Potency
- 1000IU/mg (50–55% of revenue, largest segment): Lower potency, lower cost. Used for general livestock (pigs, cattle, sheep, horses). Bulk API for veterinary pharmaceutical manufacturers. Dominant in Asia-Pacific (China, India, Southeast Asia).
- 5000IU/mg (35–40% of revenue, fastest-growing at 5–6% CAGR): Higher potency, higher cost. Used for high-value livestock (embryo transfer, superovulation). Preferred for assisted reproductive technologies (ART). Growing demand for premium breeding programs.
- Others (5–10% of revenue): Custom potency (2000IU/mg, 3000IU/mg) for specific applications, research.
Market Segmentation by Animal Species
- Pigs (Swine) (35–40% of revenue, largest segment): Estrus synchronization (sows, gilts) for fixed-time artificial insemination (FTAI). Ovulation induction (timed breeding). Superovulation (embryo transfer, genetic improvement). High volume (global pork production 120M+ tons annually). Used in China (largest pork producer), Europe, North America, Brazil.
- Cattle (30–35% of revenue): Beef cattle (estrus synchronization, FTAI). Dairy cattle (ovulation induction, embryo transfer). Superovulation for embryo transfer (genetic improvement). Used in US, Brazil, Argentina, Australia, Europe.
- Sheep (10–15% of revenue): Estrus synchronization (out-of-season breeding). Ovulation induction. Superovulation for embryo transfer. Used in Australia, New Zealand, UK, China.
- Horses (5–10% of revenue): Estrus synchronization (mares). Ovulation induction (timed breeding). Embryo transfer. Used in US, Europe, Australia, Middle East.
- Other Animals (5–10% of revenue): Goats, rabbits, laboratory animals (rats, mice) for research.
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Batch-to-Batch Variability – PMSG potency (FSH:LH ratio) varies by mare (individual variation, gestation stage), extraction batch (purification efficiency), and bioassay (animal variation). Quality control (QC) for consistency (potency, purity, sterility, endotoxin). Animal Welfare & Ethical Sourcing – PMSG extracted from pregnant mare serum (mares slaughtered for meat, blood collected). Ethical concerns (animal welfare). Alternative sources (recombinant eCG – equine chorionic gonadotropin) under development. Regulatory Compliance – EMA (European Medicines Agency), FDA-CVM (US Center for Veterinary Medicine), CFIA (Canadian Food Inspection Agency). GMP (Good Manufacturing Practice) for API manufacturing. Stability testing (shelf life 2–3 years). Supply Chain & Raw Material – pregnant mare serum availability (dependent on horse slaughter industry). Seasonal variation (breeding season). Geographic concentration (China, South America, Eastern Europe). Alternative sources (recombinant, synthetic) reduce dependence on animal serum.
独家观察: 5000IU/mg High-Potency PMSG API Fastest-Growing Segment for Embryo Transfer & Superovulation
An original observation from this analysis is the double-digit growth (5–6% CAGR) of high-potency (5000IU/mg) PMSG API for embryo transfer (ET) and superovulation in cattle, sheep, and horses . High-potency API requires lower injection volume (reduced injection site reactions), higher biological activity (better superovulation response), and premium pricing (2–3× 1000IU/mg). High-potency segment projected 45%+ of PMSG API revenue by 2030 (vs. 35% in 2025). Additionally, recombinant eCG (equine chorionic gonadotropin) is emerging as an alternative to animal-derived PMSG (consistent potency, no animal welfare concerns, scalable manufacturing). Recombinant eCG has higher cost (2–5× PMSG) but is used for high-value applications (embryo transfer in cattle, horses). Recombinant segment projected 10–15% of gonadotropin API market by 2028.
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and animal health investors, the PMSG API market represents a steady-growth (4.6% CAGR), veterinary API opportunity anchored by livestock productivity, assisted reproductive technologies, and global animal protein demand. Key strategies include:
- Investment in high-potency (5000IU/mg) PMSG API for embryo transfer and superovulation (fastest-growing segment).
- Development of recombinant eCG (equine chorionic gonadotropin) for consistent potency, animal welfare compliance, and scalable manufacturing.
- Expansion into cattle and swine segments (largest volume) for estrus synchronization, FTAI, and ovulation induction.
- Geographic expansion into Asia-Pacific (China, India, Southeast Asia) for pork production growth, North America and Europe for embryo transfer (cattle, horses).
Companies that successfully combine high biological potency, batch-to-batch consistency, and regulatory compliance will capture share in a $183 million market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
